Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults

OBJECTIVE: A recent study raises concerns that dipeptidyl peptidase 4 inhibitors (DPP4i) are associated with increased risk of inflammatory bowel disease (IBD). We evaluated the association between new use of DPP4i and IBD risk compared with other second-line antihyperglycemics. RESEARCH DESIGN AND...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Diabetes Care
Huvudupphovsmän: Wang, Tiansheng, Yang, Jeff Y., Buse, John B., Pate, Virginia, Tang, Huilin, Barnes, Edward L., Sandler, Robert S., Stürmer, Til
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Diabetes Association 2019
Ämnen:
Epidemiology/Health Services Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804610/
https://ncbi.nlm.nih.gov/pubmed/31471377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc19-0162
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk